Li J, Tang Z Y, Liu K D, Schroder C H
Liver Cancer Institute, Shanghai Medical University.
Zhonghua Yi Xue Za Zhi. 1994 Sep;74(9):533-5, 582.
A mouse monoclonal antibody directed against hepatitis B virus (HBV) X protein (HBxAg) was prepared. The antibody was used to screen by immunohistochemistry 50 liver tissue sections from patients with hepatocellular carcinoma (HCC), and 15 patients with chronic active hepatitis (CAH). 28 of 50(56%) samples were HBxAg positive in tumor tissues. The positive rates of HBxAg only in tumor tissues or in adjacent nontumor tissues were 24% and 16%. HBsAg was detected in 16% of cases in tumor tissues and 74% in surrounding nontumor tissues. In CAH samples, the positive rates of HBxAg and HBsAg were 6.6% and 73.3%. HBcAg was only detected in nontumor surrounding liver tissues, the positive rates being 18%. In CAH samples, no HBcAg was detected. The results showed that HBxAg is a common marker in liver tissue from patients with HBV-related HCC. The findings of HBxAg in the absence of detectable HBsAg and HBcAg in the liver tissues suggested that HBxAg could be independent of HBV replication and implied that the synthesis of HBxAg may be directed from integrated HBV DNA templates. It is possible to use antiHBx monoclonal antibody as a carrier for the targeting therapy of HCC.
制备了一种针对乙型肝炎病毒（HBV）X蛋白（HBxAg）的小鼠单克隆抗体。该抗体用于通过免疫组织化学方法筛查50例肝细胞癌（HCC）患者和15例慢性活动性肝炎（CAH）患者的肝组织切片。50个样本中有28个（56%）肿瘤组织中HBxAg呈阳性。仅在肿瘤组织或相邻非肿瘤组织中HBxAg的阳性率分别为24%和16%。肿瘤组织中16%的病例检测到HBsAg，周围非肿瘤组织中74%检测到HBsAg。在CAH样本中，HBxAg和HBsAg的阳性率分别为6.6%和73.3%。仅在肿瘤周围肝组织中检测到HBcAg，阳性率为18%。在CAH样本中未检测到HBcAg。结果表明，HBxAg是HBV相关HCC患者肝组织中的常见标志物。肝组织中在未检测到可检测的HBsAg和HBcAg的情况下发现HBxAg，提示HBxAg可能独立于HBV复制，意味着HBxAg的合成可能由整合的HBV DNA模板指导。有可能将抗HBx单克隆抗体用作HCC靶向治疗的载体。
